Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) major shareholder Ltd Nirland sold 1,016,823 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $0.12, for a total transaction of $122,018.76. Following the completion of the transaction, the insider now owns 11,483,177 shares of the company’s stock, valued at $1,377,981.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Ltd Nirland also recently made the following trade(s):
- On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.10, for a total transaction of $33,317.70.
Conduit Pharmaceuticals Stock Performance
CDT stock traded down $0.01 on Wednesday, reaching $0.10. The company’s stock had a trading volume of 4,309,752 shares, compared to its average volume of 4,470,719. The firm has a fifty day moving average of $0.16 and a two-hundred day moving average of $1.60. Conduit Pharmaceuticals Inc. has a 52 week low of $0.10 and a 52 week high of $8.75.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.
Check Out Our Latest Report on Conduit Pharmaceuticals
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Further Reading
- Five stocks we like better than Conduit Pharmaceuticals
- How to Use the MarketBeat Excel Dividend Calculator
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What Are Dividend Contenders? Investing in Dividend Contenders
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What is the Euro STOXX 50 Index?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
